Ten days oral treatment of CIA mice with the zonulin antagonist larazotide shortly before the onset of arthritis prevented the observed increase in intestinal barrier permeability for FITC-Dextran (FD4) and attenuated arthritis symptoms (Fig. 5a, b). This evidence concerns the gene HP and arthritic joint disease.